Do people with ME/CFS and joint hypermobility represent a disease subgroup? An analysis using registry data.
Mudie, Kathleen, Ramiller, Allison, Whittaker, Sadie et al. · Frontiers in neurology · 2024 · DOI
Quick Summary
This study looked at whether ME/CFS patients with loose, flexible joints (joint hypermobility) form a distinct group with different symptoms and health impacts. Researchers surveyed 815 ME/CFS patients and found that about 16% had joint hypermobility. These patients reported worse quality of life, more pain, and more symptoms affecting their nervous system, thinking, digestion, and muscles compared to ME/CFS patients without joint hypermobility.
Why It Matters
ME/CFS is highly heterogeneous, and identifying clinical subgroups could enable better diagnosis and targeted treatment strategies. This study provides evidence that ME/CFS patients with joint hypermobility—particularly those with concurrent EDS—may represent a distinct subgroup requiring specialized assessment and management approaches, potentially improving clinical outcomes.
Observed Findings
15.5% of ME/CFS registry participants met criteria for joint hypermobility based on self-reported Beighton scores.
JH+ participants were more frequently female and reported higher rates of EDS, POTS, and family history of EDS.
JH+ participants reported significantly worse health-related quality of life, particularly in physical functioning and pain domains.
JH+ participants experienced higher burden of autonomic, neurocognitive, headache, gut, and musculoskeletal symptoms.
Sensitivity analysis suggested ME/CFS with concurrent JH+ and EDS was associated with more severe symptoms and greater functional impairment.
Inferred Conclusions
ME/CFS patients with joint hypermobility represent a clinically distinct subgroup with more severe symptomatology and reduced quality of life.
The overlap between ME/CFS, joint hypermobility, and EDS suggests these conditions may share common pathophysiological mechanisms worth investigating.
Comprehensive clinical assessment for joint hypermobility and connective tissue disorders should be integrated into ME/CFS evaluation protocols.
Remaining Questions
What are the underlying biological mechanisms linking joint hypermobility, ME/CFS, and autonomic/neurocognitive dysfunction?
What This Study Does Not Prove
This study does not establish that joint hypermobility causes ME/CFS or is responsible for worse outcomes—it only shows an association. Self-assessed Beighton scores lack clinical validation and may not accurately reflect true hypermobility status. The cross-sectional design cannot determine temporal relationships or whether the associations reflect shared underlying biological mechanisms.
Does validated clinical assessment of hypermobility (rather than self-reported Beighton scores) confirm these associations and their clinical significance?
Are specific therapeutic interventions more effective for ME/CFS patients with versus without joint hypermobility?
What proportion of ME/CFS with JH+ also meet formal diagnostic criteria for hEDS or other connective tissue disorders?